Targeting VEGF receptors in kidney cancer.
Linehan
W Marston
WM
D000077784:Axitinib; D017322:Clinical Trials, Phase II as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics
D007093:Imidazoles; D007191:Indazoles; D000077784:Axitinib; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D040262:Receptors, Vascular Endothelial Growth Factor